Fatty Liver Blood Tests & Imaging: How to Detect It Early

You might know the feeling: a slight pressure under your right ribs, afternoon fatigue, and the lingering thought that your diet and exercise habits could have been better in recent years. Fatty liver disease is one of the most common chronic liver conditions. It causes damage silently: fat accumulates in the liver cells over years without causing any noticeable symptoms.

Many people rely on standard liver enzymes from their primary care physician. However, normal results do not rule out a fatty liver. A single blood test is not enough to accurately assess your liver health.

A reliable assessment requires three components: meaningful fatty liver blood tests, liver imaging, and an evaluation of your metabolic risk profile.

What Is Fatty Liver Disease? MASLD, MetALD, and the Silent Risk

The liver performs around 500 functions in the body. It filters metabolic byproducts, stores glycogen and proteins, produces bile, and regulates blood sugar. If too much fat accumulates in its cells, the organ comes under pressure. Medically, this is known as hepatic steatosis. Since 2023, these conditions have been grouped under the umbrella term steatotic liver disease (SLD) and are differentiated by their underlying cause:

• Metabolic dysfunction-associated steatotic liver disease (MASLD): The most common form. It develops in connection with at least one cardiometabolic risk factor, such as excess weight, insulin resistance, high blood pressure, or a lipid metabolism disorder. It was previously known as "non-alcoholic fatty liver disease" (NAFLD).
• MetALD: A mixed form where both metabolic risk factors and increased alcohol consumption play a role.
• Alcohol-associated liver disease (ALD): Here, alcohol is the primary cause of fat accumulation.

Estimates suggest that around 30% of adults worldwide are affected by MASLD or NAFLD; similar prevalence rates are assumed for Germany and other Western nations. Many are completely unaware of it. In its early stages, the process can often be reversed. Adjustments to diet, exercise, and body weight are frequently enough to achieve this.

Why Early Detection Matters

Fatty liver disease develops gradually and can progress over years if left untreated:

1. Simple steatosis (MASLD): Pure fat accumulation without significant inflammation.
2. Steatohepatitis (MASH): In addition to fat accumulation, inflammation and cell damage occur in the liver.
3. Liver fibrosis: Chronic inflammation leads to progressive scarring of the liver tissue.
4. Liver cirrhosis: In the end stage, the liver hardens, its structure is severely altered, and its function is significantly impaired. The risk of liver cancer (hepatocellular carcinoma, HCC) increases substantially.

The most critical factor for the prognosis is the degree of fibrosis. Detecting or ruling this out early is a central goal of modern preventive diagnostics. Furthermore, MASLD is associated with an increased risk of cardiovascular disease and type 2 diabetes. When you think about your liver, you are simultaneously thinking about your overall metabolic health.

Fatty Liver Blood Tests: What ALT, AST, and GGT Actually Reveal

Classic liver enzymes provide an initial clue. However, they are often insufficient for a reliable diagnosis.

Other Important Blood Markers in the Context of Fatty Liver

In addition to isolated liver enzymes, markers that describe your overall metabolic situation are important:

• HOMA Index: This value, calculated from fasting insulin and fasting blood sugar, is an established indicator of insulin resistance. This is one of the key drivers of fatty liver disease.
• Triglycerides: Elevated blood lipids are a classic risk factor and frequently occur alongside MASLD.
• Ferritin: This iron storage marker can also be elevated in the presence of inflammation and metabolic dysfunction, though it is non-specific.

Why Normal Liver Enzymes Can Be Misleading

You can have a fatty liver even if your ALT, AST, and GGT are within the reference range.

Pure fat accumulation does not necessarily lead to the release of liver enzymes. In practice, this means: an ALT of 28 U/l is considered unremarkable for men in most laboratories (up to about 35 U/l). At the same time, the fat content of the liver can be 20% or more. Even with advanced inflammation (MASH) or early fibrosis, these values frequently remain within the reference range.

The study by Fracanzani et al. (2008) demonstrated exactly this scenario: patients with normal transaminases still had an increased risk of advanced liver disease, especially if insulin resistance or diabetes was also present.

A single blood test is therefore not a reliable criterion for ruling out the disease.

Modern Diagnostics: Ultrasound, FibroScan, and MRI Compared

Since fatty liver blood tests alone are not enough, imaging comes into play. It assesses the liver structure directly.

Ultrasound reliably detects fat accumulation only when the fat content reaches approximately 20 to 30%. Below that, the examination provides hints at best. Nevertheless, an abdominal ultrasound is a sensible starting point: it shows within minutes whether the liver is fatty or if other structural abnormalities are present. An extended abdominal ultrasound, which also evaluates the liver, is therefore part of the YEARS Core® Program.

Understanding Risk Scores: What FIB-4 and Fatty Liver Index (FLI) Mean

To better assess individual risk, doctors use non-invasive scores that combine various laboratory values and parameters.

• Fatty Liver Index (FLI): Calculated from BMI, waist circumference, GGT, and triglycerides. A value below 30 makes a fatty liver unlikely, while a value of 60 or above makes it likely. It serves as a simple screening tool.
• FIB-4 Score: This is a clinically central score for assessing fibrosis risk. It is calculated from age, AST, ALT, and platelet count. A value below 1.3 is considered a low risk for advanced fibrosis (for individuals aged 65 and older, a higher threshold of about 2.0 is usually applied). It provides an initial orientation but does not replace a medical evaluation.

Modern guidelines recommend a step-by-step approach: first, the FIB-4 score is determined for at-risk individuals. If this falls into an unclear or elevated range, the next step follows, such as liver elastography (FibroScan®).

Who Should Get Tested for Fatty Liver Disease?

A targeted evaluation makes sense if you have one or more of the following risk factors:

• Overweight or obesity, especially abdominal fat
• Type 2 diabetes or prediabetes
• Known insulin resistance
• Metabolic syndrome (a combination of abdominal fat, high blood pressure, and impaired glucose and lipid metabolism)
• Elevated triglycerides or low HDL cholesterol
• High blood pressure

Even slim individuals can develop a fatty liver ("Lean MASLD") if metabolic dysfunction is present. Your overall risk profile is what matters, not just your BMI.

Early Detection of Fatty Liver Disease at YEARS

At YEARS, we view your liver health in the context of your entire metabolism. Our goal is to identify risks early so they can be addressed in a timely manner.

The YEARS Core® Program (€1,900) provides you with a solid data foundation for this:

• Comprehensive laboratory panel (87+ biomarkers): This includes liver enzymes as well as metabolic markers like the HOMA Index, ferritin, and parameters of lipid and glucose metabolism.
• Ultrasound imaging: As part of the extended abdominal ultrasound, the YEARS Medical Team also evaluates the liver, looking for signs of steatosis and other abnormalities.

Liver elastography (FibroScan®) is not part of the described YEARS services. In the event of abnormal findings, the medical team may recommend further evaluation.

For a more comprehensive analysis, the YEARS Evolve® Program (€7,600) additionally offers a whole-body MRI, which can make structural abnormalities of the liver and other organs visible.

All results are compiled in your personal Health Report and clearly contextualized during a strategy consultation with the YEARS Medical Team (about 2 weeks after your visit). You go home with a foundation for concrete next steps.

Do you want to assess your liver and metabolic status? Schedule a consultation to find the diagnostic approach that is right for you.

A Blood Test Alone Does Not Provide Certainty

A fatty liver cannot be reliably diagnosed or ruled out with a single blood test. The assessment only becomes robust through a combination of your metabolic risk profile, meaningful laboratory values (like the HOMA Index), and an imaging examination such as an ultrasound.

If you have risk factors, it pays to look at your liver and metabolism early. Anyone who starts having their markers checked every one to two years at age 35 builds a meaningful trend line before any symptoms appear.

---

Frequently Asked Questions (FAQ)

Can I have a fatty liver even if my liver enzymes are normal? Yes. A relevant portion of people with MASLD have normal liver enzymes (ALT, AST). Even more advanced changes can be present despite unremarkable blood tests. Normal values are therefore not a free pass.

Which blood test is best for detecting a fatty liver? There is no single "best" blood test. In addition to liver enzymes, metabolic markers like the HOMA Index (insulin resistance) and triglycerides are highly informative. To assess the risk of scarring, the FIB-4 score is a central tool.

When is an ultrasound recommended if a fatty liver is suspected? An ultrasound is generally sensible if you have abnormal liver enzymes, metabolic risk factors (e.g., excess weight, diabetes), or a justified medical suspicion. It is one of the most important and widely available initial examinations for detecting steatosis, though it is less sensitive for mild fat accumulation.

Can a fatty liver be reversed? A simple fatty liver without relevant inflammation, in particular, can often recede. A weight reduction of about 5% of your body weight measurably lowers liver fat content. For a body weight of 90 kg (approx. 198 lbs), this corresponds to about 4.5 kg (10 lbs). From 7 to 10% weight loss, inflammatory activity (MASH) frequently improves as well; a regression of fibrosis is more likely observed starting at around a 10% weight loss, meaning about 9 kg (20 lbs) for a 90 kg starting weight. The individual progression varies and should be medically supervised.

This article is for general informational purposes only and does not replace individual medical advice, diagnosis, or treatment. The content is based on the scientific consensus at the time of publication.

Sources

• Bedogni, G., Bellentani, S., Miglioli, L., et al. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 33.
• EASL–EASD–EASO. (2024). Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 81(3), 492–542.
• Fracanzani, A. L., Valenti, L., Bugianesi, E., et al. (2008). Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology, 48(3), 792–798.
• Rinella, M. E., Lazarus, J. V., Ratziu, V., et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 79(6), 1542–1556.
• Riazi, K., Azhari, H., Charette, J. H., et al. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 7(9), 851–861.